Lantheus Medical Imaging Release: CaRES Study Published in the Journal of the American Society of Echocardiography Further Demonstrates the Safety and Tolerability of Ultrasound Contrast Agent DEFINITY® in a Large and Diverse Patient Population  
7/2/2012 10:00:27 AM

NO. BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced the publication of the results from the CaRES multicenter safety registry for its ultrasound imaging agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension.1 The CaRES (Contrast Echocardiography REgistry for Safety Surveillance) study, found that DEFINITY® was well-tolerated in patients of different types undergoing clinically indicated DEFINITY®-enhanced echocardiography in a broad range of typical clinical settings. The results were published in the July 2012 issue of the Journal of the American Society of Echocardiography (Weiss et al., 2012).